Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT07854782Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ALN-CIDEB in metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment Emergent Adverse Events at 64 weeks and Severity of Treatment Emergent Adverse Events at 64 weeks. Started Oct 2026; status: recruiting.
02
Drugs
ALN-CIDEB
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07854782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854782.